New hope for kids with rare blood disorders: benralizumab trial launches

NCT ID NCT06512883

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 22, 2026 · Updated 5 times

Summary

This Phase 3 trial tests the drug benralizumab (Fasenra) in children aged 6 to 17 with two rare eosinophilic diseases: EGPA and HES. The study aims to see if the drug is safe, how it works in the body, and whether it can help control the disease. Fourteen children will receive injections every 4 weeks, with researchers monitoring side effects and remission rates.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: benralizumab (Fasenra)
What this could lead to: If successful, this could provide a treatment option to control eosinophilic diseases in children, reducing symptoms and reliance on steroids.
What could go wrong: This is a small, open-label trial with only 14 participants, so results may not apply broadly. Side effects or lack of efficacy are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

eosinophilic granulomatosis with polyangiitis hypereosinophilic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA) HYPEREOSINOPHILIA SYNDROME (HES)

Contacts and locations

Locations

Research Site
RECRUITING

Aurora, Colorado, 80045, United States
Research Site
NOT_YET_RECRUITING

Cincinnati, Ohio, 45229, United States
Research Site
RECRUITING

Highland Hills, Ohio, 44106-2624, United States
Research Site
RECRUITING

São Paulo, 01232-010, Brazil
Research Site
RECRUITING

Toronto, Ontario, M5G1X8, Canada
Research Site
NOT_YET_RECRUITING

Lille, 59037, France
Research Site
NOT_YET_RECRUITING

Montpellier, 34295, France
Research Site
NOT_YET_RECRUITING

Ahmedabad, 380052, India
Research Site
RECRUITING

Petah Tikva, 49202, Israel
Research Site
RECRUITING

Guadalajara, 44620, Mexico
Research Site
NOT_YET_RECRUITING

Rotterdam, 3015 GD, Netherlands
Research Site
NOT_YET_RECRUITING

Kielce, 25-734, Poland
Research Site
NOT_YET_RECRUITING

Warsaw, 04-730, Poland
Research Site
RECRUITING

Altındağ, 06230, Turkey (Türkiye)
Research Site
RECRUITING

Istanbul, 34093, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.